Low-Dose p38 MAPK Inhibitor Reduces Amyloid Plaque Burden
Solution Overview
Problem
Current treatments for Alzheimer's disease, particularly p38 MAPK inhibitors, face challenges in effectively reducing amyloid plaque burden while avoiding adverse effects and neuroinflammation, due to the complexity of the disease and redundancy in inflammatory pathways.
Innovation Solution
Administering a low dose of a selective p38 MAPK inhibitor, such as VX-745, to reduce amyloid plaque burden and inhibit MAPT phosphorylation without inducing neuroinflammation, by targeting the p38 MAPK pathway to modulate microglial activation and Aβ clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If a p38 MAPK inhibitor is administered to reduce amyloid plaque burden, then the amyloid plaque area decreases, but neuroinflammation and adverse effects may occur
Solution Approach 1:
The patent applies parameter changes by adjusting the dosage of p38 MAPK inhibitor to a low dose range, which modifies the therapeutic parameter to achieve plaque reduction while minimizing neuroinflammatory side effects. This dose optimization resolves the contradiction between effective plaque clearance and avoidance of harmful neuroinflammation.
2Quantity of substance
If a p38 MAPK inhibitor is used to clear Aβ plaques, then amyloid burden is reduced, but the complexity of inflammatory pathways makes effective treatment difficult
Solution Approach 1:
The patent extracts and targets the specific p38 MAPK pathway from the complex network of inflammatory pathways. By focusing on this single key pathway rather than attempting to modulate all inflammatory pathways simultaneously, the invention simplifies the therapeutic approach while maintaining effectiveness in clearing Aβ plaques.
3Manufacturing precision
If a selective p38 MAPK inhibitor is administered at low dose, then MAPT phosphorylation is inhibited and plaques are reduced, but the therapeutic efficacy must be maintained without adverse effects
Solution Approach 1:
The patent applies partial action by using a low dose of p38 MAPK inhibitor that is sufficient to inhibit MAPT phosphorylation and reduce plaque burden, but not excessive enough to cause adverse neuroinflammatory effects. This partial dosing strategy maintains therapeutic efficacy while improving safety and reliability.
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.